UNSPSC 51182062: Nandrolone undecylate

This classification denotes a therapeutic androgen and anabolic steroid C29H46O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K64MCF1I9Z, chemically known as estr-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17.beta.)-, but more generally known as nandrolone undecylate, which bears US NIH Compound Identifier 94193. European Medicines Agency schedules Nandrolone undecylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03388MIG.

Most nations, for tariff and trade purposes, schedule nandrolone undecylate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE UNDECYLATE remains US FDA's Preferred Term for this commodity. Nandrolone undecylate bears US NLM identifiers UMLS ID C0068398 and NCI Concept Code C95974. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C.

UNSPSC 51182062 Nandrolone undecylate is a Commodity code covering a specific anabolic steroid pharmaceutical product. State and local governments procure this and related injectable pharmaceuticals primarily through cooperative purchasing vehicles that consolidate demand across multiple jurisdictions and establish master agreements with manufacturers for distribution through authorized pharmaceutical wholesalers. The scope of work involves pharmaceutical manufacturers supplying products with specified National Drug Codes (NDCs), packaging configurations, and manufacturing certifications to meet regulatory and supply-chain security requirements. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances, with the latter serving as administrative vehicles for participating state and local health systems, correctional facilities, and other government healthcare operations across multiple jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, seeking manufacturers for generic multi-source pharmaceuticals and over-the-counter products, with a response deadline of March 26, 2026 and contract effectiveness of July 1, 2026. The solicitation covers participating facilities in Minnesota and Oregon and requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, and accept a 3 percent administrative fee on all contract purchases. Evaluation weighting favors price competitiveness (75 percent), with the remainder distributed across fixed pricing, compliance with data format and EDI requirements, and fee acceptance. Contract terms span two years for new vendors with optional MMCAP extensions, or alignment with incumbent expiration dates through June 30, 2028.